AEMD - Aethlon Medical, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AEMD

AETHLON MEDICAL, INC.

NASDAQ

$6.55

▲ UP 1.63% (0.10)

KEY STATISTICS

Market Cap$3.40 M

52w High$40.50

52w Low$1.41

Dividend Yield—

Frequency—

P/E-0.45

Volume53.94K

Shares Out.526.71K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James Frakes

COMPENSATION 2026

Salary$500,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$326,922

Total$826,922

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 4, 1999

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$1.50

Target Low$1.50

Target Median$1.50

Target Consensus$1.50

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-08-04	Reverse	1:5
2025-10-20	Reverse	1:10
2025-06-09	Reverse	1:8
2023-10-05	Reverse	1:10
2019-10-15	Reverse	1:15
2015-04-14	Reverse	1:50

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VXF

0.00%

183

INSTITUTIONAL OWNERSHIP

SHARES OWNED

21.02%

HOLDERS

TOP 8 OF 19 · RANKED BY POSITION SIZE

Geode Capital Management, LLC

Cordasco Financial Network

PRICE

$6.55 ▲ UP 1.63% (+$0.10)

OVERLAYS

About Aethlon Medical, Inc.

https://www.aethlonmedical.com ↗

Aethlon Medical, Inc. develops innovative medical devices like the Hemopurifier to diagnose and treat serious diseases, including viruses like COVID-19, through collaborations such as with UPMC Hillman Cancer Center.

INDUSTRY

Medical - Devices

A PRODUCT AETHLON MEDICAL, INC. IS KNOWN FOR

Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a FDA-designated breakthrough medical device that filters harmful viruses and exosomes from blood, aiming to treat cancer and severe viral infections.

COMPETITORS

COMPETITOR

Aethlon Medical in 2025

SENTIMENT: + POSITIVE

INNOVATION · AUGUST 2025

Aethlon Medical Stock Surges Over 60% After Announcing Positive Results from First Cohort of Australian Cancer Trial

Aethlon Medical, Inc. announced the successful completion of the first cohort in its Australian clinical trial for the Hemopurifier® in treating cancer patients. The positive safety and feasibility data, coupled with a significant reduction in operating expenses, sparked major investor optimism and led to a dramatic single-day increase in the company's stock price.

RESTRUCTURING · Q2 2025 · IN PROGRESS

Aethlon Medical Implements Aggressive Cost-Cutting Program to Extend Operational Runway and Focus on Core Oncology Trial

In 2025, Aethlon Medical executed a significant strategic shift by aggressively reducing operating expenses, including a 48% year-over-year decrease in the second fiscal quarter, to preserve capital. This intentional restructuring, which included a reduction in headcount, was implemented to extend the company's financial runway while maintaining a strategic focus on advancing its core clinical program for the Hemopurifier® in oncology.